Literature DB >> 16554102

The role of Epstein-Barr virus in acute and chronic hepatitis.

Uta Drebber1, Hans U Kasper, Joanna Krupacz, Katharina Haferkamp, Michael A Kern, Hans M Steffen, Maria Quasdorff, Axel Zur Hausen, Margarete Odenthal, Hans P Dienes.   

Abstract

BACKGROUND/AIMS: Epstein-Barr virus has a seroprevalence of more than 80% world wide and is known to be associated with hepatitis. However, little is known about the underlying pathogenesis and immunmechanisms and no standard diagnostic criteria to diagnose EBV-hepatitis are available.
METHODS: We collected liver biopsies (n=21) with the tentative diagnosis of EBV induced hepatitis according to pathological changes and traceable EBV genome by PCR. Correlation with serological data revealed acute in seven cases, convalescent in two cases, past EBV infection in six cases. Viral RNA was visualised by in situ hybridisation within nuclei of lymphocytes.
RESULTS: In seven of 68 liver biopsies with the diagnosis 'liver disease of unknown aetiology' EBV genome in the tissue was demonstrated indicating a possible role for EBV in the induction of hepatitis or a trapping of infected lymphocytes within the liver. In a control group of 20 EBV-seropositive patients with steatohepatitis EBV-DNA PCR of the liver tissue was negative. Immunohistochemistry identified CD3 and CD8 positive T-lymphocytes as the main lymphocytic infiltrate in EBV hepatitis.
CONCLUSIONS: EBV hepatitis should be taken into consideration in case of typical histopathological changes and a positive DNA PCR of liver biopsy. Serological confirmation of the diagnosis is inevitable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554102     DOI: 10.1016/j.jhep.2006.02.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  Review.

Authors:  Nahum Méndez-Sánchez; Norberto C Chávez-Tapia; Daniel Zamora-Valdés; Misael Uribe
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-02

2.  Acute hepatitis due to epstein-barr virus in an immunocompetent patient.

Authors:  Neha Pagidipati; Keith L Obstein; Rachel Rucker-Schmidt; Robert D Odze; Christopher C Thompson
Journal:  Dig Dis Sci       Date:  2009-05-21       Impact factor: 3.199

Review 3.  [Current problems of hepatitis].

Authors:  H P Dienes; U Drebber
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

4.  Severe EBV hepatitis treated with valganciclovir.

Authors:  R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi
Journal:  Infection       Date:  2012-07-27       Impact factor: 3.553

5.  Murine gamma herpes virus 68 infection promotes fatty liver formation and hepatic insulin resistance in C57BL/6J mice.

Authors:  Lei Zhao; Ya-Xi Chen; Zac Varghese; Ai-Long Huang; Ren-Kuan Tang; Bei Jia; John F Moorhead; Jian-Ping Gong; Xiong Z Ruan
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

Review 6.  Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group.

Authors:  Jessica L Mellinger; Lorenzo Rossaro; Willscott E Naugler; Satish N Nadig; Henry Appelman; William M Lee; Robert J Fontana
Journal:  Dig Dis Sci       Date:  2014-01-25       Impact factor: 3.199

Review 7.  Liver involvement in systemic infection.

Authors:  Masami Minemura; Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2014-09-27

8.  Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.

Authors:  Mihaela Petrova; Maria Muhtarova; Maria Nikolova; Svetoslav Magaev; Hristo Taskov; Diana Nikolovska; Zahariy Krastev
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 9.  Epstein-Barr virus: silent companion or causative agent of chronic liver disease?

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

Review 10.  [Histopathology in liver transplantation].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.